Candida News and Research

RSS

IPC PAS‘s chemical sensor can rapidly and effectively detect fungal infections

Fungal infections are a serious problem in modern health care. A critical factor in their successful treatment is time: the faster they are detected, the more effectively dangerous infections can be prevented.

28 Apr 2016

Novel antibiotics to overcome antibacterial resistance

Small and innovative pharmaceutical companies, with products in early stages of development, presented some of their novel approaches and antimicrobial therapies under development during a dedicated session at the annual congress (ECCMID) of the European Society of Clinical Microbiology and Infectious Diseases(ESCMID) in Amsterdam.

13 Apr 2016

Use of OTC medication not always a smart decision for yeast infection

Itching, burning, redness—a yeast infection can be a total pain. While they aren't life-threatening, yeast infections are irritating—both physically and mentally. So, when undesirable symptoms appear 'down there,' should you consult your physician or self diagnose and treat with over-the-counter medications?

9 Mar 2016

Bacteria lurking in dental water lines

Bacteria lurking in the water lines at the dentist's office are tougher than we thought, according to a new paper published in Water Research. The study reveals that the disinfectants recommended by companies that manufacture the water lines don't actually shift all the bacteria in the lines, which means they're never completely clean.

17 Feb 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

Novel anti-inflammatory agents could control hyper-inflammatory responses to fungal infection

The most frequent fungal threat to humans, Candida albicans, is a common cause oral and genital infection. The fungal infections are often worsened by overwhelming inflammatory responses in the body and cause high mortality among risk groups. Umeå University doctoral student Ava Hosseinzadeh has discovered two novel anti-inflammatory agents, an antioxidant and an anti-inflammatory molecule, which could be used to control the hyper-inflammatory responses to the fungal infection.

12 Jan 2016

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Candidiasis needs to be treated early, aggressively to help vulnerable hospitalized patients

One of the most common causes of healthcare-associated infections, candidiasis is a serious, life-threatening fungal infection that needs to be treated early, aggressively and appropriately, note updated guidelines released by the Infectious Diseases Society of America and published in the journal Clinical Infectious Diseases.

17 Dec 2015

U of T researchers discover mysterious fungus that defends against neighbouring bacteria

Researchers at the University of Toronto examined fungi in the mucus of patients with cystic fibrosis and discovered how one particularly cunning fungal species has evolved to defend itself against neighbouring bacteria.

21 Nov 2015

Creating a new paradigm for management of yeast infections

Yeasts are unicellular microorganisms classified within the Fungi kingdom. They are well known for their use in baking, winemaking and beer brewing fermentation, but some species of yeast are opportunistic pathogens that can cause infections in humans. "Today, yeast infections are poorly understood, difficult to diagnose, and are becoming increasingly frequent and serious, affecting over 300 million people worldwide.

26 Sep 2015

Radboud university medical center reveals how BCG vaccine works against tuberculosis

Not only the acquired immune system but also the innate immune system has a memory. And the BCG vaccine against tuberculosis can stimulate this memory. After a BCG vaccination the innate immune system responds better to a wide range of other infections. Mihai Netea and colleagues from Radboud university medical center discovered and described how that works. They think that the old vaccine could be useful for specific target groups, such as the elderly.

23 Sep 2015

Pitt scientists find faster method to identify pathogens

There are plenty of ways in the lab to determine which bug is bugging you when you're sick. The University of Pittsburgh's Xinyu Liu, Sanford Asher, and colleagues may have found a faster method.

9 Sep 2015

A hearty bowl of instant oatmeal helps control food intake at lunch

A new study revealed that your cereal choice at breakfast might have an impact on how much you eat for lunch. Newly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.

20 Aug 2015

LA BioMed's Nagendra Mishra to be honored with 2015 ICAAC Young Investigator Award

Nagendra Mishra, PhD, a Los Angeles Biomedical Research Institute researcher will be honored by the American Society of Microbiology with a 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy Young Investigator Award during the conference Sept. 17-21 in San Diego.

11 Aug 2015

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.

30 Jul 2015

Europe has increasing prevalence of fungal resistance, warns ESCMID

The European Society of Clinical Microbiology and Infectious Disease – an organization that explores the risks and best practices in infectious disease – is imploring global healthcare professionals and bodies to take a more active role in the growing problem of fungal resistance.

28 Jul 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

24 Jul 2015

Researchers discover role of RORC mutations in patients with candidiasis and mycobacteriosis

The discovery of bi-allelic mutations in RORC in patients with candidiasis and mycobacteriosis revealed the pivotal role of RORC in mucocutaneous immunity to Candida and in systemic immunity to Mycobacterium in humans.

13 Jul 2015

WPI-led study provides clues to new ways to treat difficult-to-cure fungal infections

A study by a multidisciplinary research team, co-directed by Worcester Polytechnic Institute, offers new insights into how virulent fungi adapt through genetic modifications to fight back against the effects of medication designed to block their spread, and how that battle leaves them temporarily weakened. These insights may provide clues to new ways to treat notoriously difficult-to-cure fungal infections like thrush and vaginitis.

7 Jul 2015

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006.

23 Jun 2015